|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02252 MEDBOT-B
Nominal 
10.620 +0.300 (+2.907%) Ranking Overview
Ranking based on 2 research report(s)
Average Ranking 2.00
|
Strong Buy (1)
0
|
Buy (2)
2
|
Hold (3)
0
|
Sell (4)
0
|
Strong Sell (5)
0
|
Previous Financial Performance
| Financial Year | 12/2023 | EPS | -106.00 RMB (cts) | |
| Net Profit | -1,012.17 RMB (MIL) | DPS | 0.00 RMB (cts) |
Consolidation Estimation
| Financial Year | Profit / (Loss) (RMB (MIL)) |
EPS/ ((LPS)(RMB (cts)) |
DPS (RMB (cts)) |
Net Asset Value per Share (RMB) |
Highest (RMB (MIL)) |
Lowest (RMB (MIL)) |
| 2024 | -589.50 | -61.50 | 0 | -- | -493.00 | -686.00 |
| 2025 | -263.00 | -27.00 | 0 | -- | -149.00 | -377.00 |
| 2026 | 6.50 | 1.00 | 0 | -- | 24.00 | -11.00 |
Profit Estimation
| Profit Estimation | Profit / (Loss) (RMB (MIL)) |
EPS*/ (LPS) (RMB (cts)) |
DPS * (RMB (cts)) |
Broker | Ranking | Target Price* (HKD) |
Update Date | |
| 2024 | -686.00 | -72.00 | -- | CITIGROUP | Buy | 28.50 | 04/09/2024 | |
| 2024 | -493.00 | -51.00 | -- | UBS | Buy | 9.50 | 11/09/2024 | |
| 2025 | -377.00 | -39.00 | -- | CITIGROUP | -- | -- | 04/09/2024 | |
| 2025 | -149.00 | -15.00 | -- | UBS | -- | -- | 11/09/2024 | |
| 2026 | -11.00 | -1.00 | -- | CITIGROUP | -- | -- | 04/09/2024 | |
| 2026 | 24.00 | 3.00 | -- | UBS | -- | -- | 11/09/2024 | |
| Remarks: | Average rating ranges from 1 to 5. The lower the figure, the higher the rating and the vice versa. |
| *EPS, DPS and Estimated Price would be adjusted upon Consolidation, Split and Bonus Issue | |
| Real time quote last updated: 24/12/2024 17:59 | |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -277,161,000 |
| %Change | -48.580% |
| EPS / (LPS) | RMB -0.290 |
| NBV Per Share (¥) | RMB 0.287 |